![]() Looking ahead, we’re excited to deliver more data and execute on milestones to maximize shareholder value,” concluded Dr. We also announced an upcoming presentation in Alzheimer’s Disease (AD) data with COYA 301 at the 2023 Keystone Symposia on Neurodegeneration to be held from May 15 – 19 that we believe may further illustrate the potential benefit of enhancing Tregs in dementia. We are excited about the potential for Arun to unlock attractive business development alliances and strategic transactions. “Subsequent to quarter end, we bolstered our leadership team with the addition of an accomplished Chief Business Officer, Arun Swaminathan, Ph.D. “In Q1, we were pleased to report promising positive clinical data for COYA 302, illustrating that this biologic combination halted disease progression in ALS patients at 24 weeks with minimal decline at 48 weeks,” stated Howard Berman, Ph.D., Chief Executive Officer of Coya. Reported preclinical data in an animal model of Alzheimer’s disease supporting the role of expanded Regulatory T Cells (Tregs) as a target for development of potential disease modifying treatments for this form of dementia Ĭlosed an Initial Public Offering of common stock and warrants on Januand overallotment option on January 25, 2023, for aggregate gross proceeds of approximately $16.4 million and net proceeds of $14.1 million. ![]() Reddy’s of COYA 302 in territories not otherwise granted to Coya Įxpanded its exclusive worldwide licensing agreement with ARScience Biotherapeutics for the development and commercialization of COYA 301 Reddy’s, COYA 301, the Company’s low dose Interleukin 2 (IL-2) product candidate to permit the commercialization by Dr. Reddy’s proposed Abatacept biosimilar, for the development of COYA 302 the Company’s combination product candidate for the treatment of certain neurodegenerative diseases, and out-licensed to Dr. Reddy’s)(NYSE: RDY), whereby Coya in-licensed Dr. Įntered into a worldwide agreement with Dr. as Chief Business Officer, who negotiated significant licensing transactions with two top-ten global pharmaceutical companies while at Alteogen, Inc. ![]() ![]() The presentation will be made at the 2023 Keystone Symposia Neurodegeneration: Biology Guiding the Next Generation of Therapeutic Development, to be held at Whistler, British Columbia, Canada, from May 15-19th, 2023 Īppointed Arun Swaminathan, Ph.D. ![]() Study data were presented at the 2023 Muscle Dystrophy Association Conference Īnnounced the presentation of results from an academic clinical study in eight patients with mild to moderate Alzheimer’s Disease (AD) with Coya’s COYA 301, its proprietary investigational biologic, evaluating its safety and tolerability, biological activity, blood biomarkers and preliminary efficacy. Q1 2023 and Recent Highlights (Unaudited)Īnnounced positive results from a proof-of-concept, open-label academic clinical study of COYA 302 in Amyotrophic Lateral Sclerosis (ALS) illustrating halting of disease progression at 24 weeks with minimal decline at 48 weeks. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the first quarter ended March 31, 2023, and provided a clinical and business update. HOUSTON-( BUSINESS WIRE)-Coya Therapeutics, Inc. ![]()
0 Comments
Leave a Reply. |